TY - JOUR AU - Lok, A. S. AU - McMahon, B. J. PY - 2009 DA - 2009// TI - Chronic hepatitis B: update 2009 JO - Hepatology. VL - 50 UR - https://doi.org/10.1002/hep.23190 DO - 10.1002/hep.23190 ID - Lok2009 ER - TY - CHAP PY - 2014 DA - 2014// TI - Hepatitis B BT - Vol ID - ref2 ER - TY - JOUR AU - Lu, F. M. AU - Zhuang, H. PY - 2009 DA - 2009// TI - Prevention of hepatitis B in China: achievements and challenges JO - Chin Med J VL - 122 ID - Lu2009 ER - TY - JOUR AU - Sung, J. J. AU - Tsoi, K. K. AU - Wong, V. W. AU - Li, K. C. AU - Chan, H. L. PY - 2008 DA - 2008// TI - Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma JO - Aliment Pharm Therap VL - 28 UR - https://doi.org/10.1111/j.1365-2036.2008.03816.x DO - 10.1111/j.1365-2036.2008.03816.x ID - Sung2008 ER - TY - JOUR AU - Liaw, Y. F. AU - Lin, S. M. AU - Chen, T. J. AU - Chien, R. N. AU - Sheen, I. S. AU - Chu, C. M. PY - 1994 DA - 1994// TI - Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial JO - J Hepatol VL - 20 UR - https://doi.org/10.1016/S0168-8278(05)80055-8 DO - 10.1016/S0168-8278(05)80055-8 ID - Liaw1994 ER - TY - JOUR PY - 2017 DA - 2017// TI - 2017 clinical practice guidelines on the management of hepatitis B virus infection JO - J Hepatol VL - 67 UR - https://doi.org/10.1016/j.jhep.2017.03.021 DO - 10.1016/j.jhep.2017.03.021 ID - ref6 ER - TY - JOUR AU - Lee, I. C. AU - Sun, C. K. AU - Su, C. W. AU - Wang, Y. J. AU - Chang, H. C. AU - Huang, H. C. PY - 2015 DA - 2015// TI - Durability of Nucleos(t)ide analogues treatment in patients with chronic hepatitis B JO - Medicine. VL - 94 UR - https://doi.org/10.1097/MD.0000000000001341 DO - 10.1097/MD.0000000000001341 ID - Lee2015 ER - TY - JOUR AU - Liaw, Y. F. AU - Jia, J. D. AU - Chan, H. L. AU - Han, K. H. AU - Tanwandee, T. AU - Chuang, W. L. PY - 2011 DA - 2011// TI - Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C JO - Hepatology. VL - 54 UR - https://doi.org/10.1002/hep.24555 DO - 10.1002/hep.24555 ID - Liaw2011 ER - TY - JOUR AU - You, C. R. AU - Lee, S. W. AU - Jang, J. W. AU - Yoon, S. K. PY - 2014 DA - 2014// TI - Update on hepatitis B virus infection JO - World J Gastroenterol VL - 20 UR - https://doi.org/10.3748/wjg.v20.i37.13293 DO - 10.3748/wjg.v20.i37.13293 ID - You2014 ER - TY - JOUR AU - Liaw, Y. F. AU - Kao, J. H. AU - Piratvisuth, T. AU - Chan, H. L. AU - Chien, R. N. AU - Liu, C. J. PY - 2012 DA - 2012// TI - Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update JO - Hepatol Int VL - 6 UR - https://doi.org/10.1007/s12072-012-9365-4 DO - 10.1007/s12072-012-9365-4 ID - Liaw2012 ER - TY - JOUR AU - Lau, G. K. AU - Piratvisuth, T. AU - Luo, K. X. AU - Marcellin, P. AU - Thongsawat, S. AU - Cooksley, G. PY - 2005 DA - 2005// TI - Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B JO - New Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043470 DO - 10.1056/NEJMoa043470 ID - Lau2005 ER - TY - JOUR AU - Tang, C. M. AU - Yu, J. PY - 2014 DA - 2014// TI - Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments JO - World J Gastroenterol VL - 20 UR - https://doi.org/10.3748/wjg.v20.i20.6262 DO - 10.3748/wjg.v20.i20.6262 ID - Tang2014 ER - TY - JOUR AU - Block, T. M. AU - Gish, R. AU - Guo, H. AU - Mehta, A. AU - Cuconati, A. AU - Thomas London, W. PY - 2013 DA - 2013// TI - Chronic hepatitis B: what should be the goal for new therapies? JO - Antivir Res VL - 98 UR - https://doi.org/10.1016/j.antiviral.2013.01.006 DO - 10.1016/j.antiviral.2013.01.006 ID - Block2013 ER - TY - JOUR AU - Xiong, Y. L. AU - Li, H. AU - Liu, F. AU - Zhang, D. AU - Ren, H. AU - Hu, P. PY - 2016 DA - 2016// TI - Efficacy of PEGylated interferon in treatment-experienced Chinese patients with HBeAg positive chronic hepatitis B JO - Hepat Mon VL - 16 UR - https://doi.org/10.5812/hepatmon.35357 DO - 10.5812/hepatmon.35357 ID - Xiong2016 ER - TY - JOUR AU - Masaki, K. AU - Suzuki, F. AU - Hara, T. AU - Kawamura, Y. AU - Sezaki, H. AU - Hosaka, T. PY - 2015 DA - 2015// TI - Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection JO - Virol J VL - 12 UR - https://doi.org/10.1186/s12985-015-0453-7 DO - 10.1186/s12985-015-0453-7 ID - Masaki2015 ER - TY - JOUR AU - Marcellin, P. AU - Bonino, F. AU - Lau, G. K. AU - Farci, P. AU - Yurdaydin, C. AU - Piratvisuth, T. PY - 2009 DA - 2009// TI - Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a JO - Gastroenterology. VL - 136 UR - https://doi.org/10.1053/j.gastro.2009.03.006 DO - 10.1053/j.gastro.2009.03.006 ID - Marcellin2009 ER - TY - JOUR PY - 2012 DA - 2012// TI - EASL clinical practice guidelines: management of chronic hepatitis B virus infection JO - J Hepatol VL - 57 UR - https://doi.org/10.1016/j.jhep.2012.02.010 DO - 10.1016/j.jhep.2012.02.010 ID - ref17 ER - TY - JOUR AU - Potthoff, A. AU - Berg, T. AU - Wedemeyer, H. PY - 2009 DA - 2009// TI - Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin JO - Scand J Gastroenterol VL - 44 UR - https://doi.org/10.3109/00365520903329585 DO - 10.3109/00365520903329585 ID - Potthoff2009 ER - TY - JOUR AU - Chen, L. i. -. P. i. n. g. PY - 2012 DA - 2012// TI - Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma JO - World Journal of Virology VL - 1 UR - https://doi.org/10.5501/wjv.v1.i6.174 DO - 10.5501/wjv.v1.i6.174 ID - Chen2012 ER - TY - JOUR AU - Cheng, J. AU - Wang, Y. AU - Hou, J. AU - Luo, D. AU - Xie, Q. AU - Ning, Q. PY - 2014 DA - 2014// TI - Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial JO - J Clin Virol VL - 61 UR - https://doi.org/10.1016/j.jcv.2014.08.008 DO - 10.1016/j.jcv.2014.08.008 ID - Cheng2014 ER - TY - JOUR AU - Wong, V. W. AU - Wong, G. L. AU - Yan, K. K. AU - Chim, A. M. AU - Chan, H. Y. AU - Tse, C. H. PY - 2010 DA - 2010// TI - Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B JO - Hepatology. VL - 51 UR - https://doi.org/10.1002/hep.23568 DO - 10.1002/hep.23568 ID - Wong2010 ER - TY - JOUR AU - Okanoue, T. AU - Shima, T. AU - Hasebe, C. AU - Karino, Y. AU - Imazeki, F. AU - Kumada, T. PY - 2016 DA - 2016// TI - Long-term follow up of peginterferon-alpha-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies JO - Hepatol Res VL - 46 UR - https://doi.org/10.1111/hepr.12638 DO - 10.1111/hepr.12638 ID - Okanoue2016 ER - TY - JOUR AU - Buster, E. H. AU - Flink, H. J. AU - Simsek, H. AU - Heathcote, E. J. AU - Sharmila, S. AU - Kitis, G. E. PY - 2009 DA - 2009// TI - Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients JO - Am J Gastroenterol VL - 104 UR - https://doi.org/10.1038/ajg.2009.371 DO - 10.1038/ajg.2009.371 ID - Buster2009 ER - TY - JOUR AU - Ma, H. AU - Yang, R. F. AU - Wei, L. PY - 2010 DA - 2010// TI - Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients JO - J Gastroenterol Hepatol VL - 25 UR - https://doi.org/10.1111/j.1440-1746.2010.06282.x DO - 10.1111/j.1440-1746.2010.06282.x ID - Ma2010 ER - TY - JOUR AU - Sarin, S. K. AU - Kumar, M. AU - Lau, G. K. AU - Abbas, Z. AU - Chan, H. L. AU - Chen, C. J. PY - 2016 DA - 2016// TI - Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update JO - Hepatol Int VL - 10 UR - https://doi.org/10.1007/s12072-015-9675-4 DO - 10.1007/s12072-015-9675-4 ID - Sarin2016 ER - TY - JOUR AU - Buster, E. H. AU - Flink, H. J. AU - Cakaloglu, Y. AU - Simon, K. AU - Trojan, J. AU - Tabak, F. PY - 2008 DA - 2008// TI - Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b JO - Gastroenterology. VL - 135 UR - https://doi.org/10.1053/j.gastro.2008.05.031 DO - 10.1053/j.gastro.2008.05.031 ID - Buster2008 ER - TY - JOUR AU - Sonneveld, M. J. AU - Rijckborst, V. AU - Boucher, C. A. AU - Hansen, B. E. AU - Janssen, H. L. PY - 2010 DA - 2010// TI - Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline JO - Hepatology. VL - 52 UR - https://doi.org/10.1002/hep.23844 DO - 10.1002/hep.23844 ID - Sonneveld2010 ER - TY - JOUR AU - Sonneveld, M. J. AU - Rijckborst, V. AU - Cakaloglu, Y. AU - Simon, K. AU - Heathcote, E. J. AU - Tabak, F. PY - 2012 DA - 2012// TI - Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-alpha2b: relation to response and HBV genotype JO - Antivir Ther VL - 17 UR - https://doi.org/10.3851/IMP1887 DO - 10.3851/IMP1887 ID - Sonneveld2012 ER - TY - JOUR AU - Wang, Y. C. AU - Yang, S. S. AU - Su, C. W. AU - Wang, Y. J. AU - Lee, K. C. AU - Huo, T. I. PY - 2016 DA - 2016// TI - Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis JO - Sci Rep VL - 6 UR - https://doi.org/10.1038/srep29605 DO - 10.1038/srep29605 ID - Wang2016 ER - TY - JOUR AU - Hsu, H. Y. AU - Tsai, H. Y. AU - Wu, T. C. AU - Chiang, C. L. AU - Ni, Y. H. AU - Chen, P. J. PY - 2008 DA - 2008// TI - Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan JO - Liver Int VL - 28 UR - https://doi.org/10.1111/j.1478-3231.2008.01746.x DO - 10.1111/j.1478-3231.2008.01746.x ID - Hsu2008 ER - TY - JOUR AU - Lin, C. C. AU - Wu, J. C. AU - Chang, T. T. AU - Huang, Y. H. AU - Wang, Y. J. AU - Tsay, S. H. PY - 2001 DA - 2001// TI - Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan JO - J Viral Hepat VL - 8 UR - https://doi.org/10.1046/j.1365-2893.2001.00320.x DO - 10.1046/j.1365-2893.2001.00320.x ID - Lin2001 ER - TY - JOUR AU - Zhao, H. AU - Kurbanov, F. AU - Wan, M. B. AU - Yin, Y. K. AU - Niu, J. Q. AU - Hou, J. L. PY - 2007 DA - 2007// TI - Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China JO - Clin Infect Dis VL - 44 UR - https://doi.org/10.1086/511042 DO - 10.1086/511042 ID - Zhao2007 ER - TY - JOUR AU - Buster, E. H. AU - Hansen, B. E. AU - Lau, G. K. AU - Piratvisuth, T. AU - Zeuzem, S. AU - Steyerberg, E. W. PY - 2009 DA - 2009// TI - Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa JO - Gastroenterology. VL - 137 UR - https://doi.org/10.1053/j.gastro.2009.08.061 DO - 10.1053/j.gastro.2009.08.061 ID - Buster2009 ER - TY - JOUR AU - Chen, C. H. AU - Lee, C. M. AU - Hung, C. H. AU - Wang, J. H. AU - Hu, T. H. AU - Changchien, C. S. PY - 2011 DA - 2011// TI - Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients JO - J Gastroenterol Hepatol VL - 26 UR - https://doi.org/10.1111/j.1440-1746.2010.06429.x DO - 10.1111/j.1440-1746.2010.06429.x ID - Chen2011 ER -